Abstract: Compounds of formula (I) ##STR1## in which X represents a group >O, >S, >C.dbd.O or >NR wherein R is hydrogen, C.sub.1-6 alkyl, phenyl or C.sub.7-12 phenalkyl, R.sub.1 and R.sub.2 each represent hydrogen or together represent an oxo group and R.sub.3, R.sub.4 and R.sub.5 each represent hydrogen or R.sub.1 represents hydrogen and two of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 together represent the second bond of a double bond joining positions 7 and 8, 8 and 9 or 9 and 10 with the remaining two of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing hydrogen, the compound optionally being in the form of a salt thereof formed with a physiologically acceptable inorganic or organic acid, are of value for the treatment of anxiety and in the improvement of learning ability and/or the reversal of amnesia.

Abstract: Compounds of formula (I) ##STR1## in which R.sub.1 represents hydrogen, a C.sub.1-6 aliphatic hydrocarbyl group or a C.sub.1-4 aliphatic hydrocarbyl group substituted by a C.sub.3-6 alicyclic hydrocarbyl group or by a phenyl group, which phenyl group is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.2 represents hydrogen, R.sub.3 represents hydrogen, a 5-or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur which is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, or a group AR wherein A is a straight chain C.sub.1-4 aliphatic hydrocarbyl group terminally substituted by R which is hydrogen, a phenyl group or a 5-or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, which phenyl or heterocyclyl group R is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.4 and R.sub.

Abstract: Compounds of formula (I) ##STR1## in which R.sub.1 represents hydrogen, a C.sub.1-6 aliphatic hydrocarbyl group or a C.sub.1-4 aliphatic hydrocarbyl group substituted by a C.sub.3-6 alicyclic hydrocarbyl group or by a phenyl group, which phenyl group is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.2 represents hydrogen, R.sub.3 represents hydrogen, a 5- or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur which is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, or a group AR wherein A is a straight chain C.sub.1-4 aliphatic hydrocarbyl group terminally substituted by R which is hydrogen, a phenyl group or a 5- or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, which phenyl or heterocyclyl group R is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.4 and R.sub.

Abstract: 1-Aryl-3-(4-1piperidyl)-indole derivatives having general formula (I), ##STR1## wherein R.sup.1 is hydrogen, halogen, alkyl, alkoxy, hydroxy, cyano, nitro, alkylthio, trifluoromethyl, trifluoromethylthio, alkylsulfonyl, amino, alkylamino or dialkylaminio; R is optionally substituted phenyl or a heteroaromatic group; and R.sup.2 is hydrogen, cycloalkyl, alkyl or alkenyl, optionally substituted with one or two hydroxy groups, or R.sup.2 is a group of formula (IV), ##STR2## wherein n is an integer of from 2-6; W is O, S or N--R.sup.3, wherein R.sup.3 is H alkyl or cycloalkyl; U is N or CH, Z is --(CH.sub.2).sub.m --, m being 2 or 3, or Z is --CH.dbd.CH--, 1,2-phenylene, or --COCH.sub.2 -- or --CSCH.sub.2 --; V is O,S,CH.sub.2, or NR.sup.4, wherein R.sup.4 is hydrogen, optionally hydroxy substituted alkyl, alkenyl or cycloalkylmethyl; are useful in alleviating, relieving or suppressing withdrawal or abstinence symptons or suppressing the dependency of a drug or a substance of abuse.

Abstract: A method for treating memory impairment is disclosed. The method comprises administering a therapeutically effective amount of a compound having the formula: ##STR1## or a pharmaceutically acceptable acid addition salt or prodrug therefor to a patient.

Abstract: A method for treating anxiety in mammals comprising administering in an effective amount to said mammal an 1-aryl-3-(4-piperidyl)-indole derivative having the general formula: ##STR1## wherein R.sup.1 is H, F, Cl, Br, methyl, methoxy or cyano; and R.sup.3 is H or methyl; or a pharmaceutical acceptable acid addition salt thereof.

Abstract: Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I ##STR1## wherein: R.sub.1 represents hydrogen or C.sub.1 -C.sub.4 alkyl;n is 1 or 2;R.sub.2 represents hydrogen or methyl, provided that one R.sub.2 is hydrogen when n is 2;R.sub.3 represents hydrogen or C.sub.1 -C.sub.2 alkyl;R.sub.4 represents C.sub.1 -C.sub.2 alkyl;R.sub.5 and R.sub.6 independently represent hydrogen or methyl;m is 0 to 3; andeach Y is in a meta or para position and independently represents hydroxy, C.sub.1 -C.sub.2 alkoxy, C.sub.1 -C.sub.2 alkyl, C.sub.1 -C.sub.2 hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position,and not pharmacologically acceptable salts thereof have memory enhancing activity and are particularly useful in the treatment of cognitive deficiencies such as senile dementia.The presently preferred compound is 3-(3'methoxyphenyl)-3-(3'-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxop iperidine (AGN 2979).

Abstract: Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-imidazolyl)-ami no]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of substituted benzamides of formula (1): ##STR1## in which: A is linear or branched C.sub.1 -C.sub.3 alkyl; allyl or diethylaminoethyl;R.sub.1 is hydrogen or methyl, andZ-- is --NH--, --O-- or --S--,and of their pharmacologically acceptable salts for modifying gastric motility.

Abstract: Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-immidazolyl)-am ino]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to the use of benzamide derivatives of the formula: ##STR1## in which: A is a diethylaminoethyl group or a group of the formula II: ##STR2## where R is a C.sub.1 -C.sub.3 alkyl, allyl, cyclopropylmethyl or cyclohexenylmethyl group,X is a chlorine or bromine atom, andZ is --NH-- or --O-- with the following condition: when Z is --O--, A is a diethylaminoethyl group, and their pharmacologically acceptable salts for the preparation of medicinal products which are useful in the treatment and prevention of disorders of the cognitive function.

Abstract: A method is provided for imhibiting loss of cognitive functon, including memory, which may or may not be associated with Alzheimer's disease, by administering an ACE inhibitor, such as captopril, fosinopril, zofenopril or ceranapril in combination with a drug that acts as serotonin receptors such as zacopride, over a prolonged period of treatment.

Abstract: The present invention relates to the application of substituted benzamides of formula (I): ##STR1## in which: A is diethylaminoethyl, 1-ethyl-2-pyrrolidinylmethyl or 1-allyl-2-pyrrolidinylmethyl;R.sub.1 is hydrogen or methyl;X is chlorine or bromine;Z is --NH-- or --O-- except when Z is --NH--,R.sub.1 is hydrogen and X is chlorine, and of their pharmacologically acceptable addition salts, as anxiolytics and antipsychotics.

Abstract: New substituted benzamides have the general formula: ##STR1## their optical isomers and their physiologically acceptable salts. The compounds are used as activators of the central nervous system.

Abstract: Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I ##STR1## wherein: R.sub.1 represents hydrogen or C.sub.1 -C.sub.4 alkyl;n is 1 or 2;R.sub.2 represents hydrogen or methyl, provided that one R.sub.2 is hydrogen when n is 2;R.sub.3 represents hydrogen or C.sub.1 -C.sub.2 alkyl;R.sub.4 represents C.sub.1 -C.sub.2 alkyl;R.sub.5 and R.sub.6 independently represent hydrogen or methyl;m is 0 to 3; and each Y is in a meta or para position and independently represents hydroxy, C.sub.1 -C.sub.2 alkoxy, C.sub.1 -C.sub.2 alkyl, C.sub.1 -C.sub.2 hydroxyalkyl, halogen, or trifluoromethyl, provided that hydroxy and alkoxy are not in the para position, and pharmacologically acceptable salts thereof have antiposychotic activity without sedative side effects. They are particularly useful in the treatment of schizophrenia.The presently preferred compound is 3-(3'methoxyphenyl)-3-(3"-N,N-dimethylaminopropyl) -4,4-dimethyl-2,6-dioxopiperidine (AGN 2979).

Abstract: New substituted benzamides have the general formula: ##STR1## A=alkyl, alkenyl, diethylaminoethyl or ##STR2## R.sub.1, R.sub.2 =H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl; R.sub.3, R.sub.4, R.sub.5, R.sub.6 =hydrogen or C.sub.1 -C.sub.6 alkyl;X=halogen;Y=H, halogen;Z=NH, oxygen or sulfur;their optical isomers and their physiologically acceptable salts. The compounds are used as activators of the central nervous system.

Abstract: The use of N-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulphamoyl benzamide to treat Parkinson's disease.